Therapy for refractory acute graft versus host disease (aGVHD) with basiliximab (BaMab) - a selective interleukin-2 receptor (IL-2R) antagonist

Moreira, V.; Bonfim, Carmen; Bitencourt, Marco A.; Setubal, D.C.; Lorenzato, Cláudia Santos; Ruiz, J.; Zanis-Netto, J.; Medeiros, Carlos Roberto de; Pasqüini, Ricardo

doi:10.1016/j.bbmt.2003.12.080

Biology of Blood and Marrow Transplantation

2004

DOI: 10.1016/j.bbmt.2003.12.080

|View full text |Cite

Therapy for refractory acute graft versus host disease (aGVHD) with basiliximab (BaMab) - a selective interleukin-2 receptor (IL-2R) antagonist

V. Moreira¹,

Carmen Bonfim²,

Marco A. Bitencourt³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2009

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MAbs such as daclizumab are a promising treatment modality for corticosteroidresistant aGVHD. To date, experience with several MAbs for the treatment of corticosteroid-resistant aGVHD has been reported including daclizumab (7)(8)(9)(10)(11), rituxumab (12), infliximab (13)(14)(15)(16)(17), basilixumab (18)(19)(20), visilizumab (21), inolimomab (22), and ABX-CBL (23). Daclizumab has been effective as a single agent in treating corticosteroid-resistant aGVHD in adults (7)(8)(9)(10).…”

mentioning

confidence: 99%

Daclizumab therapy for children with corticosteroid‐resistant acute graft‐vs.‐host disease

Schechter¹,

Afzal²,

Finkelstein³

et al. 2009

Pediatric Transplantation

View full text Add to dashboard Cite

MAbs such as daclizumab have shown promising results in the treatment of corticosteroid-resistant aGVHD. Data describing the efficacy of MAbs in children are limited. We describe the efficacy of daclizumab in children with corticosteroid-resistant aGVHD. Seventeen children (0.4-16.2 yr) received daclizumab for aGVHD. Safety was evaluated in all 17. Response was evaluated in the 15 children who received a full course of daclizumab. A PR was defined as improvement of aGVHD symptoms in at least one organ without worsening in other organs. We observed an overall response rate (CR plus PR) of 40% (6/15). Four children had a CR and two had a PR. aGVHD involving the gut had the highest response rate (five of 10; 50%). Adverse effects attributed to daclizumab were limited to an episode of reactive arthritis. Mortality was high (47%; eight of 17) though five of the six responders to daclizumab survived. The mean length of follow-up in the surviving nine patients was 32 months (range seven to 48). We conclude that daclizumab is effective in the treatment of children with corticosteroid-resistant aGVHD, especially in patients with gut involvement.

show abstract

mentioning

confidence: 99%

Daclizumab therapy for children with corticosteroid‐resistant acute graft‐vs.‐host disease

Schechter¹,

Afzal²,

Finkelstein³

et al. 2009

Pediatric Transplantation

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Therapy for refractory acute graft versus host disease (aGVHD) with basiliximab (BaMab) - a selective interleukin-2 receptor (IL-2R) antagonist

Cited by 1 publication

References 0 publications

Daclizumab therapy for children with corticosteroid‐resistant acute graft‐vs.‐host disease

Daclizumab therapy for children with corticosteroid‐resistant acute graft‐vs.‐host disease

Contact Info

Product

Resources

About